State Street
AUPH icon

State Street’s Aurinia Pharmaceuticals AUPH Stock Holding History

State Street’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.9M Buy
2,589,615
+62,516
+2% +$999K ﹤0.01% 1927
2026
Q1 		$37.5M Buy
2,527,099
+25,107
+1% +$367K ﹤0.01% 1902
2025
Q4 		$39.9M Sell
2,501,992
-191,763
-7% -$2.72M ﹤0.01% 1866
2025
Q3 		$29.8M Sell
2,693,755
-101,335
-4% -$1.11M ﹤0.01% 2018
2025
Q2 		$23.7M Sell
2,795,090
-56,076
-2% -$450K ﹤0.01% 2096
2025
Q1 		$22.9M Sell
2,851,166
-66,873
-2% -$542K ﹤0.01% 2061
2024
Q4 		$26.2M Sell
2,918,039
-27,021
-0.9% -$220K ﹤0.01% 2064
2024
Q3 		$21.6M Buy
2,945,060
+64,949
+2% +$403K ﹤0.01% 2161
2024
Q2 		$16.4M Buy
2,880,111
+109,247
+4% +$575K ﹤0.01% 2268
2024
Q1 		$13.9M Buy
2,770,864
+66,482
+2% +$451K ﹤0.01% 2387
2023
Q4 		$24.3M Buy
2,704,382
+104,847
+4% +$863K ﹤0.01% 2104
2023
Q3 		$20.2M Sell
2,599,535
-32,951
-1% -$322K ﹤0.01% 2175
2023
Q2 		$25.5M Buy
2,632,486
+52,474
+2% +$545K ﹤0.01% 2093
2023
Q1 		$28.3M Buy
2,580,012
+130,465
+5% +$1.15M ﹤0.01% 1998
2022
Q4 		$10.6M Buy
2,449,547
+8,113
+0.3% +$47.1K ﹤0.01% 2658
2022
Q3 		$18.4M Buy
2,441,434
+53,572
+2% +$464K ﹤0.01% 2290
2022
Q2 		$24M Buy
2,387,862
+1,863,594
+355% +$20.8M ﹤0.01% 2123
2022
Q1 		$6.49M Buy
524,268
+144,586
+38% +$2.23M ﹤0.01% 3049
2021
Q4 		$8.68M Buy
379,682
+4,944
+1% +$117K ﹤0.01% 2988
2021
Q3 		$8.29M Buy
+374,738
New +$5.95M ﹤0.01% 2985

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street's AUPH Position: Q2 2026 in Review

State Street increased its Aurinia Pharmaceuticals (AUPH) stake by 2.5% in Q2 2026, buying an estimated $999K and bringing the position to 2,589,615 shares worth $43.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1927.

State Street first reported a position in AUPH in Q3 2021 and has held it in 20 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • State Street held 2,589,615 shares of Aurinia Pharmaceuticals worth $43.9M as of Q2 2026.
  • State Street bought 62,516 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $999K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1927 holding.
  • State Street first reported a position in Aurinia Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.